prof. MUDr. Pavel Klener, Ph.D.
| Address: | |
|---|---|
| Office: | Ústav patologické fyziologie 1. LF UK |
| Fax: | |
| Additional information: | https://is.cuni.cz/webapps/whois2/osoba/1655044543316478 |
| Faculty: | First Faculty of Medicine |
| Department: | Institute of Pathological Physiology First Faculty of Medicine Charles University (11-00180) |
| Phone: | |
| E-mail: | pavel.klener2@lf1.cuni.cz |
| Consultation hours: | po dohodě kdykoliv |
| Courses Schedule Opinion survey results Noticeboard | |
| Faculty: | Second Faculty of Medicine |
| Department: | Units out of CU (13-999) - external specialist |
| Parent department: | () |
| Phone: | |
| E-mail: | |
| Courses Schedule Noticeboard | |
| Faculty: | Faculty of Science |
| Department: | Department of Cell Biology (31-151) - external specialist |
| Parent department: | non-academic workplace (31-999) |
| Phone: | |
| E-mail: | |
| Consultation hours: | |
| Courses Schedule Opinion survey results Announced theses Supervised theses | |
| Faculty: | Third Faculty of Medicine |
| Department: | Mimofakultní pracoviště (12-JINE) |
| Phone: | |
| E-mail: | |
| Courses Schedule |
| Currently supervised PhD students | |||||||||||||||||||
  Doctoral student |  Faculty | Study programme | Branch of study | Student since | Status of studies | Dissertation | |||||||||||||
hidden | 3.LF | Molecular and Cellular Biology, Genetics and Virology | Molecular and Cellular Biology, Genetics and Virology | 2017 | studying | Role PI3K-AKT signaling in biology and drug resistence of non-Hodgkin lymphoma | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2016 | study interrupted | Role mikroprostředí a hypoxie na deregulaci apoptózy u agresivních lymfomů | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2019 | studying | Study of novel drugable targets in experimental therapy of malignant lymphomas on murine models | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2016 | studying | Molecular-cytogenetic analysis of aggressive lymphomas | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2015 | studying | Studium molekulárních mechanismů a patofyziologických aspektů terapie agresivních lymfomů zaměřené na cílenou indukci apoptózy a/nebo inhibici buněčného cyklu | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2023 | studying | Experimental treatment approaches of aggressive lymphoproliferative malignancies and impact of microenvironment in the development of drug resistance | |||||||||||||
| hidden | 1.LF | Cell Biology and Pathology | Cell Biology and Pathology | 2022 | studying | Antibody drug conjugates in experimental therapy of aggressive lymphomas | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2023 | studying | Role of hypoxia, hypoxia-inducible factors HIF1 and their regulators in the biology of aggressive lymphomas | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2023 | studying | Novel prognostic and predictive factors in hematologic malignancies at diagnosis and during therapy | |||||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2021 | studying | New drugable targets in experimental therapy of acute lymphoblastic leukemias and aggressive non-hodgkin lymphomas | |||||||||||||
| Previously supervised PhD students | |||||||||||||||||||
| Doctoral student | Faculty | Study programme | Branch of study | Student since | Year of completion | Status of studies | Dissertation | Supervisor from | Supervisor until | Current supervisor | |||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2018 | studying | The pathophysiology and prognostic factors of indolent lymphomas | 01.10.2018 | 05.12.2018 | prof. MUDr. Marek Trněný, CSc. | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2013 | 2022 | graduated | Patient-derived xenograft models of human lymphomas for experimental immunotherapy | 25.07.2013 | 19.01.2023 | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2012 | 2021 | graduated | The Role of Antiangiogenic Therapy in Mantle Cell Lymphoma | 01.10.2012 | 20.01.2022 | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2012 | 2016 | discontinued | Role mikroprostředí a angiogeneze v přežití,růstu,šíření a terapeutické odpovědi lymfomu z plášťových buněk | 01.10.2012 | 06.09.2017 | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2022 | studying | Next-generation CAR T-cells for experimental immunotherapy of hematologic malignancies | 08.09.2022 | 30.11.2023 | MUDr. Magdalena Zikmundová, Ph.D. | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2009 | 2013 | graduated | Resensitization of leukemia and lymphoma cells to trail-induced apoptosis | 01.10.2009 | 17.10.2013 | ||||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2009 | 2022 | discontinued | Studium mechanismů interakcí-buňka-buňka a buňka-materiál pro tkáňové inženýrství | 29.09.2009 | 03.03.2015 | Mgr. Elena Filová, Ph.D. | |||||||||
| hidden | 1.LF | Human Physiology and Pathophysiology | Human Physiology and Pathophysiology | 2009 | 2017 | graduated | Experimental therapy of B-cell Non-Hodgkin's lymphonas. | 29.09.2009 | 18.01.2018 | ||||||||||
| Announced topics | |||||||||||||||||||
| Dissertation | Faculty | ||||||||||||||||||
| 1.LF | |||||||||||||||||||
| Study of novel drugable targets in experimental therapy of malignant lymphomas on murine models | 1.LF | ||||||||||||||||||